Auxogyn Announces Oral Presentations on the Eeva™ Test at the Annual Meeting of the American Society for Reproductive Medicine

Clinical and Scientific Presence Demonstrate Continued Commitment of Auxogyn and its Clinic Partners to Advancing Science and Research in IVF Field

Oct 20, 2014, 18:00 ET from Auxogyn

HONOLULU, Oct. 20, 2014 /PRNewswire/ -- Auxogyn, a company focused on advancing women's reproductive health by translating scientific discoveries into clinical solutions, today announced oral presentations of the latest data on its Eeva™ Test this week at the 70th Annual Meeting of the American Society For Reproductive Medicine (ASRM) 2014 being held this week in Honolulu, Hawaii.

"We are very excited to share the results of this research with our colleagues at ASRM," said Lissa Goldenstein, CEO and President of Auxogyn.  "The Eeva Test was clinically validated prior to its commercial availability and provides valuable information for embryo assessment to clinicians and patients. The research being presented at ASRM this week shows potential for the Eeva Test that may expand its indications in the future and lead to great advances in the field of reproductive health."

Two abstracts submitted by Auxogyn clinic partners were accepted as oral presentations at ASRM.  The first, entitled "Improved implantation rates using the time-lapse-enabled Eeva Test as an adjunct to morphology for day 3 transfer," is being presented by Dr. David Adamson today, October 20th, at 5:15PM.

"The clinical data from this study shows promise that the Eeva Test may have capabilities beyond blastocyst prediction," said Dr. G. David Adamson, reproductive endocrinologist, CEO of Advanced Reproductive Care and past president of both the American Society of Reproductive Medicine (ASRM) and Society of Assisted Reproductive Technologies (SART). "Our preliminary study findings showed that patients receiving day 3 embryo transfers based on adjunctive use of the Eeva Test achieved significantly improved implantation rates, although more clinical data is needed to substantiate these early results."

The second abstract, entitled "Correlation between computer-automated time-lapse analysis results and implantation success in patients of different age groups: a blinded, multi-center study," will be presented on the podium by Matthew (Tex) VerMilyea, PhD, Scientific Director of Fertility Associates of New Zealand and previous Director of IVF & Andrology Laboratories, Penn Fertility Care at University of Pennsylvania, on Wednesday October 22nd at 5PM.

"Auxogyn is committed to advancing reproductive medicine through scientific and clinical rigor, as evidenced though its support of these ongoing research studies, as well as our recent FDA clearance of the Eeva System as a first-of-its-kind device," stated Goldenstein. "We're dedicated to improving IVF outcomes and will continue to work with our clinics to assist in advancing the field."

Auxogyn is exhibiting in the exhibit hall at ASRM, booth #935 and is hosting a product theater on the Eeva System also today at 1PM on the Exhibit Floor.  Entitled "Beyond Time-Lapse – The Eeva Test, First in Class" Dr. Claudio Benadiva, MD, HCLD (ABB) and Director of IVF Laboratory at The Center for Advanced Reproductive Services (CARS) and Clinical Professor of Obstetrics and Gynecology at the University of Connecticut, will be presenting CARS experience with the Eeva System and Eeva Test as part of the MERGE Study.

Full session details and data presentation listings for the 2014 meeting can be found on the ASRM website at

About Auxogyn

Auxogyn is a leader in reproductive health that provides novel scientific and clinically validated solutions to IVF clinicians and their patients by translating scientific discoveries in early embryo development into clinical tools that improve patient outcome. The company's flagship product, the Eeva Test, delivers objective information regarding embryo development that IVF clinicians and patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information, visit and follow the company on Twitter @Auxogyn.

About the Eeva System
Auxogyn's Eeva System a first-in-class, non-invasive device cleared by the FDA to aid in embryo selection.  The Eeva Test is scientifically derived and clinically validated to identify embryos with the greatest developmental potential when used adjunctively to traditional morphology in women with multiple embryos deemed appropriate for transfer or freezing.  Utilizing proprietary software and sophisticated computer vision technology, the Eeva Test automatically analyzes embryo development against scientifically and clinically validated cell-division timing parameters.  With the Eeva Test's quantitative data on each embryo's development potential, IVF clinicians can optimize the treatment path for their patients undergoing IVF procedures.  Auxogyn received FDA clearance for the Eeva System in June, 2014 and will make it available in the U.S. later this year. The Eeva System also received the CE mark in July 2012, and it is currently available for use in selected countries in the EU and Canada.

For more information regarding the Eeva Test, please visit

SOURCE Auxogyn